On January 4, 2022 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, reported Jim Caruso, president and CEO and Jarrod Longcor, CBO, will participate in a fireside chat at the H.C. Wainwright Bioconnect conference taking place virtually January 10-13, 2022 (Press release, Cellectar Biosciences, JAN 4, 2022, https://investor.cellectar.com/news/detail/282/cellectar-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-conference [SID1234598058]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available on demand beginning at 7:00 am ET on January 10, 2022. To access and view the event, investors are encouraged to register by clicking on this registration link.

The event also will be available on the News & Media section of the company’s website.

On January 4, 2022 Bristol Myers Squibb (NYSE: BMY) reported that the company will present at J.P. Morgan’s 40th Annual Virtual Healthcare Conference on Monday, January 10, 2022 (Press release, Bristol-Myers Squibb, JAN 4, 2022, View Source [SID1234598057]). Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company at 7:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be webcast simultaneously at View Source with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.

On January 4, 2022 Boston Scientific Corporation (NYSE: BSX) reported that it will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 (Press release, Boston Scientific, JAN 4, 2022, View Source [SID1234598055]). Mike Mahoney, chairman and chief executive officer, will present at ­­­8:15 a.m. EST . Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, in a question-and-answer session with the host analyst.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Wednesday February 2, 2022 Boston Scientific will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2021. The call will begin at 8:00 a.m. EST, hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on February 2 prior to the conference call.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.com. The replay will be available approximately one hour following the completion of each event.

On January 4, 2022 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January (Press release, BioMarin, JAN 4, 2022, View Source [SID1234598054]). To access the live webcasts, please visit: View Source An archived version of the presentations will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2022 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET (Press release, BioCryst Pharmaceuticals, JAN 4, 2022, View Source [SID1234598053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.